{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:41:23Z","timestamp":1760834483803,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.jocn.2020.04.105","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T07:58:57Z","timestamp":1588233537000},"page":"249-250","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Hypoalbuminemia in Guillain-Barr\u00e9 syndrome"],"prefix":"10.1016","volume":"77","author":[{"given":"Linpei","family":"Jia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2020.04.105_b0005","doi-asserted-by":"crossref","unstructured":"Shalman A, Savir S, Mechnik Steen Y, Ovanyan A, Boniel N, Koyfman L, et al. Albuminlevelsas a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barresyndrome (GBS). J Clin Neurosci 2020;74:247\u20139","DOI":"10.1016\/j.jocn.2020.01.067"},{"issue":"2","key":"10.1016\/j.jocn.2020.04.105_b0010","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamaneurol.2016.4480","article-title":"Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barr\u00e9 Syndrome","volume":"74","author":"Fokkink","year":"2017","journal-title":"JAMA Neurol"},{"issue":"11","key":"10.1016\/j.jocn.2020.04.105_b0015","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1177\/000313481708301123","article-title":"Hypoalbuminemia and Clinical Outcomes: What is the Mechanism behind the Relationship?","volume":"83","author":"Kim","year":"2017","journal-title":"Am Surg"},{"issue":"suppl 3","key":"10.1016\/j.jocn.2020.04.105_b0020","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1007\/s11739-012-0802-0","article-title":"Hypoalbuminemia","volume":"7","author":"Gatta","year":"2012","journal-title":"Intern Emerg Med"},{"issue":"5","key":"10.1016\/j.jocn.2020.04.105_b0025","first-page":"347","article-title":"New guidelines for hospital-acquired pneumonia\/ventilator-associated pneumonia: USA vs","volume":"24","author":"Martin-Loeches","year":"2018","journal-title":"Europe. Curr Opin Crit Care"},{"key":"10.1016\/j.jocn.2020.04.105_b0030","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/357412","article-title":"The role of apolipoprotein E in Guillain-Barr\u00e9 syndrome and experimental autoimmune neuritis","volume":"2010","author":"Zhang","year":"2010","journal-title":"J Biomed Biotechnol"},{"issue":"8","key":"10.1016\/j.jocn.2020.04.105_b0035","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2020.04.105_b0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0404.2011.01511.x","article-title":"Altered cerebrospinal fluid index of prealbumin, fibrinogen, and haptoglobin in patients with Guillain-Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy","volume":"125","author":"Zhang","year":"2012","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.jocn.2020.04.105_b0045","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ncl.2013.01.005","article-title":"Guillain-Barr\u00e9 Syndrome and Variants","volume":"31","author":"Dimachkie","year":"2013","journal-title":"Neurol Clin"},{"issue":"7","key":"10.1016\/j.jocn.2020.04.105_b0050","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaneurol.2017.0563","article-title":"Could Albumin Be a Biomarker to Monitor the Effect of Intravenous Immunoglobulin on Guillain-Barr\u00e9 Syndrome?","volume":"74","author":"Wang","year":"2017","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.jocn.2020.04.105_b0055","first-page":"96","article-title":"Liver function disturbances in Guillain-Barr\u00e9 syndrome: a prospective longitudinal study in 100 patients","volume":"46","author":"Oomes","year":"1996","journal-title":"Dutch Guillain-Barr\u00e9 study group. Neurology"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586820305415?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586820305415?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:22:42Z","timestamp":1760822562000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586820305415"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":11,"alternative-id":["S0967586820305415"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2020.04.105","relation":{},"ISSN":["0967-5868"],"issn-type":[{"type":"print","value":"0967-5868"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypoalbuminemia in Guillain-Barr\u00e9 syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2020.04.105","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}